Easy, reliable, high-quality, and cost-effective testing for SARS-CoV-2 (COVID-19), in compliance with local regulatory requirements, is crucial to enabling millions of passengers to complete their journeys in comfort and safety. Eurofins has rapidly developed a broad network of around 500 testing centers across Europe and intends to have established around 1,000 testing centers by early July.

Eurofins’ network of testing centers covers major traveling hubs and provides testing accessibility in a broad variety of locations such as supermarkets, business parks, and residential areas, improving customer proximity and ease of testing.

Eurofins also operates mobile testing centers to further increase availability and access. Such mobile facilities can be used by municipal authorities to reduce pressure on existing testing centers by quickly adding sampling capacity. These mobile collection centers can each process up to 200 PCR tests per day. Eurofins has already launched this service in Belgium, France, and Germany.

Additionally, to further support testing, in particular for European travel this summer, Eurofins has created an intuitive web portal for travelers to book testing appointments and access their testing information, not only in their country of origin but also at destination locations. All of Eurofins’ testing centers are listed on a single landing page, identifying nearby testing locations.

This portal is available in 12 languages; https://www.eurofins.com/covid19-travel-regulations-testing-stations/

Eurofins is committed to offering the best possible testing services to all travelers looking for a seamless, comfortable, and safe travel experience. Eurofins has also invested in laboratory capacity and IT solutions that will ensure fast turn-around times for test results (as low as a few hours from receipt of sample at the laboratory for gold-standard PCR Tests). Alongside Eurofins’ home-testing offering (where supported by Health Authorities), the Group’s extensive testing centers and mobile sample facilities enable Eurofins to offer an easy and comprehensive experience for international travelers across Europe and the world.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

Investor Relations Eurofins Scientific Phone: +32 2 766 1620 E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 25 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.